Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients with Type 2 Diabetes and CKD

Launched by ASSIUT UNIVERSITY · Feb 6, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how a medication called Dapagliflozin affects certain health markers in patients with Type 2 diabetes and chronic kidney disease (CKD). Specifically, the study will compare the effects of Dapagliflozin to a placebo (a treatment that has no active effect) on red blood cell production, iron levels, and inflammation in the body. By understanding these effects, researchers hope to gain insights into how Dapagliflozin could help improve health for people with these conditions.

To participate in the trial, individuals must be at least 18 years old and have Type 2 diabetes with specific health measurements, such as a certain level of protein in their urine and kidney function within a set range. However, people with Type 1 diabetes, kidney disease not related to diabetes, or very low blood levels will not be eligible. Those who join the study can expect to be monitored closely for changes in their health markers throughout the trial, which is currently not yet recruiting participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Eligible participants were aged \>18 years and diagnosed with Type 2 diabetes participants we required to have urinary albumin-creatinine ratio (UACR ) of 30_3500 mg /g ,eGFR of 20_ 80 ml/min/ 1.73 m , and HbA1c of 7.0 _ 11.0 % at screening
• Exclusion Criteria:
• • type 1 diabetes, non-diabetes kidney disease and patient with HB \< 9